SEARCH

SEARCH BY CITATION

References

  • 1
    Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001;344: 3037.
  • 2
    Canonica GW. Introduction to the nasal and pulmonary allergy cascade. Allergy 2002;57(Suppl. 75):812.
  • 3
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl.):S147S334.
  • 4
    Sekiya T, Yamada H, Yamaguchi M et al. Increased levels of TH2-type CC chemokine thymus and activation-regulated chemokine (TARC) in serum and induced sputum of asthmatics. Allergy 2002;57: 173177.
  • 5
    Terada N, Nomura T, Kim WJ et al. Expression of C-C chemokine TARC in human nasal mucosa and its regulation by cytokines. Clin Exp Allergy 2001;31: 18091812.
  • 6
    Kanwar S, Johnston B, Kubes P. Leukotriene C4/D4 induces P-selectin and sialyl Lewis (x)-dependent alterations in leukocyte kinetics in vivo. Circ Res 1995;77: 879887.
  • 7
    Strachan D, Sibbald B, Weiland S et al. Worldwide variations in prevalence of symptoms of allergic rhinoconjunctivitis in children: the International Study of Asthma and Allergies in Childhood (ISAAC). Pediatr Allergy Immunol 1997;8: 161176.
  • 8
    Ciprandi G, Vizzaccaro A, Cirillo I, Crimi P, Canonica G. Increase of asthma and allergic rhinitis prevalence in young Italian men. Int Arch Allergy Immunol 1996;111: 279283.
  • 9
    Aberg N, Hesselmar B, Aberg B, Eriksson B. Increase of asthma, allergic rhinitis and eczema in Swedish schoolchildren between 1979 and 1991. Clin Exp Allergy 1995;25: 815819.
  • 10
    Evans R III, Mullally DI, Wilson RW et al. National trends in the morbidity and mortality of asthma in the US. Prevalence, hospitalization and death from asthma over two decades: 1965–1984. Chest 1987;91: 65S74S.
  • 11
    Aberg N. Asthma and allergic rhinitis in Swedish conscripts. Clin Exp Allergy 1989;19: 5963.
  • 12
    Broder I, Higgins MW, Mathews KP, Keller JB. Epidemiology of asthma and allergic rhinitis in a total community, Tecumseh, Michigan. IV. Natural history. J Allergy Clin Immunol 1974;54: 100110.
  • 13
    Settipane G, Settipane RJ, Hagy GW. Long term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students. Allergy Proc 1994;15: 2125.
  • 14
    Anderson HR, Pottier AC, Strachan DP. Asthma from birth to age 23: incidence and relationship to prior and concurrent atopic status. Thorax 1992;47: 537542.
  • 15
    Jenkins MA, Hopper JL, Flander LB et al. The associations between childhood asthma, and atopy, and parental asthma, hay fever and smoking. Paediatr Perinat Epidemiol 1993;7: 6776.
  • 16
    Lombardi C, Passalacqua G, Gargioni S et al. The natural history of respiratory allergy: a follow-up study of 99 patients up to 10 years. Respir Med 2001;95: 912.
  • 17
    Corren J. Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997;99: S781S786.
  • 18
    Ball TM, Castro-Rodriguez JA, Griffith KA, Holberg CJ, Martinez FD, Wright AL. Siblings, day-care attendance, and the risk of asthma and wheezing during childhood. N Engl J Med 2000;343: 538543.
  • 19
    Openshaw PJ, Hewitt C. Protective and harmful effects of viral infections in childhood on wheezing disorders and asthma. Am J Respir Crit Care Med 2000;162(2: 2):S40S43.
  • 20
    Karmaus W, Botezan C. Does a higher number of siblings protect against the development of allergy and asthma? A review. J Epidemiol Community Health 2002;56: 209217.
  • 21
    Cookson W. The alliance of genes and environment in asthma and allergy. Nature 1999;402(Suppl. 6760):B5B11.
  • 22
    Warner JA, Jones AC, Miles EA, Colwell BM, Warner JO. Prenatal origins of asthma and allergy. Ciba Found Symp 1997;206: 220228,228–232(discussion).
  • 23
    Eriksson NE, Holmen A. Skin prick tests with standardized extracts of inhalant allergens in 7099 adult patients with asthma or rhinitis. Cross-sensitizations and relationships to age, sex, month of birth and year of testing. J Invest Allergol Clin Immunol 1996;6: 3646.
  • 24
    Quoix E, Bessot JC, Kopferschmitt-Kubler MC, Fraisse P, Pauli G. Positive skin tests to aero-allergens and month of birth. Allergy 1988;43: 127131.
  • 25
    Cookson WO. Asthma genetics. Chest 2002;121(Suppl. 3):7S13S.
  • 26
    Toda M, Ono SJ. Genomics and proteomics of allergic disease. Immunology 2002;106: 110.
  • 27
    Marsh DG, Hsu SH, Roebber M et al. HLA-Dw2: a genetic marker for human immune response to short ragweed pollen allergen Ra5. I. Response resulting primarily from natural antigenic exposure. J Exp Med, 1982;155: 14391451.
  • 28
    Hill MR, Cookson WO. A new variant of the beta subunit of the high-affinity receptor for immunoglobulin E (Fc epsilon RI–beta E237G): associations with measures of atopy and bronchial hyper-responsiveness. Hum Mol Genet 1996;5: 959962.
  • 29
    Marsh DG, Neely JD, Breazeale DR et al. Linkage analysis of IL4 and other chromosome 5q31.1 markers and total serum immunoglobulin E concentrations. Science 1994;264: 11521156.
  • 30
    Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999;20: 976983.
  • 31
    Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ 2002;324: 763.
  • 32
    Salvi S. Pollution and allergic airways disease. Curr Opin Allergy Clin Immunol 2001;1: 3541.
  • 33
    Lodrup Carlsen KC, Carlsen KH. Effects of maternal and early tobacco exposure on the development of asthma and airway hyperreactivity. Curr Opin Allergy Clin Immunol 2001;1: 139143.
  • 34
    Piedimonte G. The association between respiratory syncytial virus infection and reactive airway disease. Respir Med 2002;96(Suppl. B):S25S29.
  • 35
    Fineman SM. The burden of allergic rhinitis, beyond dollars and cents. Ann Allergy Asthma Immunol 2002;88(Suppl. 1):27.
  • 36
    Dessi P, Allaert FA, Urbinelli R, Verriere JL. Medico-economic aspects of the management of perennial allergic rhinitis in general medicine. Allerg Immunol (Paris) 1998;30: 277283.
  • 37
    Kessler RC, Almeida DM, Berglund P, Stang P. Pollen and mold exposure impairs the work performance of employees with allergic rhinitis. Ann Allergy Asthma Immunol 2001;87: 289295.
  • 38
    Crystal-Peters J, Crown WH, Goetzel RZ, Schutt DC. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000;6: 373378.
  • 39
    Cuffel B, Wamboldt M, Borish L, Kennedy S, Crystal-Peters J. Economic consequences of comorbid depression, anxiety, and allergic rhinitis. Psychosomatics 1999;40: 491496.
  • 40
    Szucs TD, Anderhub H, Rutishauser M. The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J 1999;13: 281286.
  • 41
    Weissflog D, Matthys H, Virchow JC Jr. Epidemiology and costs of bronchial asthma and chronic bronchitis in Germany. Dtsch Med Wochenschr 2001;126: 803808.
  • 42
    Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985–1994. J Allergy Clin Immunol 2000;106: 493499.
  • 43
    Nowak D, Volmer T, Wettengel R. Bronchial asthma – a cost of illness analysis. Pneumologie 1996;50: 364371.
  • 44
    Smith C. A national estimates of the economic costs of asthma. Am J Respir Crit Care Med 1997;156: 797793.
  • 45
    Gallefoss F, Bakke PS. Cost-effectiveness of self-management in asthmatics: a 1-yr follow-up randomized, controlled trial. Eur Respir J 2001;17: 206213.
  • 46
    Serra-Batlles J, Plaza V, Morejon E, Comella A, Brugues J. Costs of asthma according to the degree of severity. Eur Respir J 1998;12: 13221326.
  • 47
    Szucs TD, Anderhub HP, Rutishauser M. Determinants of health care costs and patterns of care of asthmatic patients in Switzerland. Schweiz Med Wochenschr 2000;130: 305313.
  • 48
    Graf von der Schulenburg JM, Greiner W, Molitor S, Kielhorn A. Cost of asthma therapy in relation to severity. An empirical study. Med Klin 1996;91: 670676.
  • 49
    Plaza V, Serra-Batlles J, Ferrer M, Morejon E. Quality of life and economic features in elderly asthmatics. Respiration 2000;67: 6570.
  • 50
    Ungar WJ, Coyte PC. Measuring productivity loss days in asthma patients. The Pharmacy Medicaton Monitoring Program Advisory Board. Health Econ 2000;9: 3746.
  • 51
    Meltzer EO. Pharmacological treatment options for allergic rhinitis and asthma. Clin Exp Allergy 1998;28(Suppl. 2):2736.
  • 52
    Barnes PJ. Effect of beta-agonists on inflammatory cells. J Allergy Clin Immunol 1999;104: S10S17.
  • 53
    Torphy TJ. Action of mediators on airway smooth muscle: functional antagonism as a mechanism for bronchodilator drugs. Agents Actions Suppl 1988;23: 3753.
  • 54
    Johnson DA, Hricik JG. The pharmacology of alpha-adrenergic decongestants. Pharmacotherapy 1993;13: 110S115S, 143S–146S(discussion).
  • 55
    Boumpas DT, Chrousos GP, Wilder RL, Cupps TR, Balow JE. Glucocorticoid therapy for immune-mediated diseases: basic and clinical correlates. Ann Intern Med 1993;119: 11981208.
  • 56
    Charlesworth EN, Massey WA, Kagey-Sobotka A, Norman PS, Lichtenstein LM. Effect of H1 receptor blockade on the early and late response to cutaneous allergen challenge. J Pharmacol Exp Ther 1992;262: 964970.
  • 57
    Bachert C. Therapeutic points of intervention and clinical implications: role of desloratadine. Allergy 2002;57(Suppl. 75):1318.
  • 58
    Huger M, Traidl-Hoffmann C, Kasche A, Ring J, Behrendt H. Influence of desloratadine on the chemotactic activity of human polymorphonuclear leukocytes. Allergy 2002;57(Suppl. 73):38.
  • 59
    Marshall G, Henninger E, Maniatis E, Ritter S, Salicru A, Messick C. Immunomodulatory effects of desloratadine: changes in type-1/type-2 cytokine expression in PBMC cultures. J Allergy Clin Immunol 2002;109(Suppl.):S206S207.
  • 60
    Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40: 7276.
  • 61
    Meltzer EO, Prenner BM, Nayak A et al. Efficacy and tolerability of once-daily 5 mg desloratadine, an H1-receptor antagonist, in patients with seasonal allergic rhinitis assessment during the spring and fall allergy season. Clin Drug Invest 2001;21: 2532.
  • 62
    Dubuske L. Once-daily desloratadine reduces the symptoms of perennial allergic rhinitis for at least 4 weeks. J Allergy Clin Immunol 2001;107: S159.
  • 63
    Baena-Cagnani C. Desloratadine improved asthma symptoms and decreased beta 2-agonist use in patients with seasonal allergic rhinitis and concomitant asthma. Allergy 2001;56(Suppl. 68):22.
  • 64
    Bachert C. Decongestant efficacy of desloratadine in patients with seasonal allergic rhinitis. Allergy 2001;56(Suppl. 65):1420.
  • 65
    Geha RS, Meltzer EO. Desloratadine: a new, nonsedating, oral antihistamine. J Allergy Clin Immunol 2001;107: 751762.
  • 66
    Horak F, Stübner P, Zieglmayer R, Moser M, Kawina A, Engelbrecht W. Decongestant activity of desloratadine versus placebo in allergic rhinitis: results from 3 single-dose, placebo-controlled, allergen chamber trials. Allergy 2001;56(Suppl. 68):79.
  • 67
    Horak F, Stübner P, Zieglmayer R, Harris AG. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109: 956961.
  • 68
    Daly A. Desloratadine reduces nasal congestion in SAR with greater magnitude than fexofenadine, cetrizine and loratadine. Allergy 2001;56(Suppl. 68):79.
  • 69
    Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001;40: 7276.
  • 70
    Data on file. Schering-Plough, 2002.